NCT03164564: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 138 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03164564 |
|---|---|
| Title | A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 7, 2017 |
| Completion date | Nov. 5, 2020 |
| Required reporting date | Nov. 5, 2021, midnight |
| Actual reporting date | March 23, 2022 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 138 |